智翔金泰：公司已收到GR1803注射液授权许可与商业化协议首付款2000万元美金

Core Viewpoint - The company has confirmed the receipt of a $20 million upfront payment related to the licensing and commercialization agreement for the GR1803 injection with Cullinan, and will recognize this revenue according to accounting policies [1] Group 1 - The company has received the $20 million upfront payment as part of the agreement with Cullinan [1] - The licensing and commercialization agreement for GR1803 injection has been signed and is in effect [1] - The company advises investors to refer to its announcements and periodic reports for detailed information [1]